SBRT 2016

Interstitial lung disease

Study

Interstitial lung disease Overall patients / % patients with ILD

SBRT dose

Radiation penumonitis

Takeda Lung cancer 2015

124 – 16%

4 x 12Gy

G2-5 19%

Ueki JTO 2015

157 – 13%

G3+ 55%

4 x 12Gy

G3+ 32% G5 21%

Bahig PRO 2016

504 – 6%

G2+ 50% G5 17%

Yoshitake Anticancer Res 2015

260 – 8%

 ILD as exclusion criteria for SBRT

/ M Guckenberger - SBRT stage I NSCLC - HICARE 2015

18